Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $17.5 million.

  • Silence Therapeutics' Gains from Investment Securities fell 929.18% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $17.5 million for FY2024, which is 442.60% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Gains from Investment Securities is $17.5 million, which was up 442.60% from $3.2 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Gains from Investment Securities registered a high of $17.5 million during FY2024, and its lowest value of $3,852 during FY2020.
  • For the 3-year period, Silence Therapeutics' Gains from Investment Securities averaged around $7.1 million, with its median value being $3.2 million (2023).
  • Data for Silence Therapeutics' Gains from Investment Securities shows a peak YoY soared of 543.40% (in 2023) over the last 5 years.
  • Silence Therapeutics' Gains from Investment Securities (Yearly) stood at $3,852 in 2020, then reached $500,000 in 2022, then skyrocketed by 543.40% to $3.2 million in 2023, then skyrocketed by 442.60% to $17.5 million in 2024.